Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Etoricoxib in Healthy Adult Subjects
NCT05532280Phase 1Completed
- Sponsor
- Future University in Egypt
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etoricoxib in osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and 1 more (2 arms), sponsored by Future University in Egypt. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve to Last Measurable Concentration at 72 hours and 1 more. Started Dec 2020; status: completed.
02
Drugs
etoricoxib
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)gouty arthritis
Beyond the preview
Go deeper on NCT05532280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532280.